BioMedNewsBreaks – CB Scientific Inc. (CBSC) Enters Definitive Agreement to Acquire Datrix LLC

CB Scientific (OTC: CBSC), engaged in providing innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced definitive purchase agreement to acquire Datrix LLC, a global ambulatory device manufacturer based in Escondido, California. Datrix brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. The acquisition further strengthens CBSC’s digital offering with the addition of an existing commercially available product line, which includes wireless mobile cardiac telemetry, cardiac event, extended and standard holter monitoring through the Datrix Sirona and VX3 devices. “We are extremely excited about our acquisition of Datrix LLC and how it enhances and strengthens the growth trajectory of our business,” said Charles Martin, CBSC CEO. “The acquisition, combined with other expansion efforts already underway, will position CBSC to play a significant role in delivering innovative diagnostic devices and testing into this ever-expanding market, further helping our company to establish a solid footprint in the worldwide remote cardiac ambulatory noninvasive ECG monitoring market.”

To view the full press release, visit https://ibn.fm/4qouJ

About CB Scientific Inc.

CB Scientific is a publicly traded company that, through its U.S. and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. For more information about the company, visit www.CBScientificInc.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies…

23 hours ago

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Emerging GLP-1 Innovation 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB:…

23 hours ago

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic…

1 day ago

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research

Kairos Pharma (NYSE American: KAPA) announced it has been named a winner in the 2026…

1 day ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of…

1 day ago